✨ Free AI Report
Serina Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Serina Therapeutics, Inc.
Company Research

Serina Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The company focuses on advancing its PO...

Analyst-debate audio for Serina Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Serina Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Early-stage biotech with promising POZ platform technology but facing significant financial and regulatory headwinds requiring...

Read the full analyst-debate transcript →
Industry Biotechnology - Neurological Therapeutics
2 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Serina Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Serina Therapeutics, Inc. Overview

Pro stress-test →

Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The company focuses on advancing its POZ platform technology with a lead program in Parkinson's disease treatment.

Strategic Profile

Pro stress-test →

The POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). The company is developing its lead candidate SER-252 for advanced Parkinson's disease in a Phase 1b registrational trial aligned with an FDA 505(b)(2) NDA pathway.

Competitive Landscape

Pro stress-test →

Serina competes in the neurological disease space against larger pharmaceutical companies and biotechs developing Parkinson's treatments. Its POZ platform differentiates it through novel drug delivery capabilities, though the company faces resource constraints compared to well-capitalized competitors. The clinical-stage status limits competitive positioning until Phase 1b trial results are achieved.

Industry Context

Serina Therapeutics, Inc. operates in Biotechnology - Neurological Therapeutics.

Key facts

Founded: 2006 · Headquarters: Huntsville, Alabama · Market cap: $18.87M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Serina Therapeutics, Inc..

  • First patient enrolled in Phase 1b registrational trial of SER-252 for advanced Parkinson's disease in February 2026
  • Stockholders' equity of only $1.6 million as of September 30, 2025, with losses in three of four recent fiscal years
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026First patient enrolled in Phase 1b registrational trial of SER-252 for advanced Parkinson's disease
  • December 2025Submitted complete response to FDA clinical hold addressing trehalose excipient formulation questions
  • +2 moreTrack every material event for Serina Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Serina Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Levodopa-based therapies and dopamine agonistsStandard-of-care Parkinson's disease treatments→Advanced neurological drug development platformsCompeting POZ-like delivery technologies for neurological indications→

Compare Serina Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Serina Therapeutics, Inc. operates in Biotechnology - Neurological Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Neurological Therapeutics research →
NEW · MCP server

Ask your AI assistant about Serina Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Serina Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Serina Therapeutics, Inc. do this quarter?”
“Is Serina Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Serina Therapeutics, Inc. do?+
Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The company focuses on advancing its PO...
What is Serina Therapeutics, Inc.'s Cyborg Score?+
Serina Therapeutics, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Serina Therapeutics, Inc.'s main competitors?+
Named competitors include Levodopa-based therapies and dopamine agonists, Advanced neurological drug development platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Serina Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Serina Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Serina Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.